医学
脾边缘带淋巴瘤
脾切除术
美罗华
内科学
淋巴瘤
累积发病率
生存分析
外科
年轻人
侵袭性淋巴瘤
入射(几何)
死亡率
存活率
回顾性队列研究
肿瘤科
总体生存率
儿科
胃肠病学
血液学
病历
化疗
脾脏
死因
作者
Ahmed Ludvigsen Al‐Mashhadi,Mikkel Runason Simonsen,Elizabeth Smyth,Rose‐Marie Amini,Bente Arboe,James R. Cerhan,Iman Chanchiri,Chan Yoon Cheah,Jonathan R Day,Toby Andrew Eyre,Anne Ortved Gang,Hervé Ghesquières,Thomas Matthew Habermann,Eliza Anne Hawkes,Steven Hwang,Ruxandra Maria Irimia,Jennifer Bøgh Jørgensen,Arushi Khurana,Claire Maquet,Mathew S. Maurer
标识
DOI:10.1038/s41408-026-01660-2
摘要
Splenic Marginal Zone Lymphoma (SMZL) is an indolent non-Hodgkin lymphoma subtype. Due to its rarity, evaluation of real-world data is necessary to inform clinical practice. In this study, adults diagnosed with SMZL between 2000 and 2018 from North America, Europe, and Australia were included and followed until death or last visit. Data were extracted from medical records and regional/national registries. In total, 987 patients with median age of 68 years were included. The 10-year overall survival (OS) estimates were 59% (95%CI: 55-63) from first-line treatment and 49% (95%CI: 43-57) from second-line treatment. First-line splenectomy ( n = 434) and rituximab monotherapy ( n = 121) were associated with an Inverse Probability of Treatment Weighting (IPTW)-adjusted 5-year failure-free survival (FFS) of 52% for splenectomy versus 42% for rituximab; HR 0.70 (95%CI: 0.44-1.13) and adjusted HR for OS of 1.09 (95%CI: 0.59-2.01). The 10-year cumulative risk of transformation from diagnosis was 15% (95%CI: 12-18) with 5-year post-transformation OS of 38% (95%CI: 29-49), and 23% (95%CI: 13-41) for transformation after previous chemotherapy. Lower rates of transformation were seen in patients receiving frontline rituximab. While frontline therapy with either splenectomy or rituximab monotherapy had similarly favorable outcomes, patients had a persistent risk of progression and transformation andsurvival after transformation was poor.
科研通智能强力驱动
Strongly Powered by AbleSci AI